The therapeutic landscape of lupus nephritis is rapidly evolving, with promising new agents expanding available options; however, high costs, limited access, and insufficient long-term data currently restrict their widespread first-line use. Future head-to-head trials and real-world studies are essential to refine treatment algorithms and improve durable renal outcomes.
Couto-Lareo et al. (Tue,) studied this question.